Irodalom:
1. Grady, W.M.: Genetic testing for high-risk colon cancer patients. Gastroenterology, 2003,124,1574-1594.
2. Bennett A, Del Tacca M.: Proceedings: prostaglandins in human colonic carcinoma. Gut 1975;16:409.
3. Jaffe BM.: Prostaglandins and cancer: an update. Prostaglandins 1974;6:453-461.
4. Waddell WR, Loughry RW.: Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-87.
5. Bertagnolli MM.: Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps
forward, one step back. Lancet Oncol 2007;8:439-443.
6. Kune GA, Kune S, Watson LF.: Colorectal cancer risk, chronic illnesses, operations, and medications:
case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48:4399-4404.
7. Giovannucci E, Egan MK, Hunter DJ, et al.: Aspirin and the risk of colorectal cancer in women. N Engl
J Med 2005;333:609-614.
8. Giovannucci E, Rimm EB, Stampfer MJ, et al.: Aspirin use and risk for colorectal cancer and adenoma
in male health professionals. Ann Intern Med 1994;121:241-246.
9. Chan AT, Giovannucci EL, Meyerhardt JA, et al.: Aspirin dose and duration of use and risk of colorectal
cancer in men. Gastroenterology. 2008;134:21-28.
10. Jacobs EJ, Thun MJ, Bain EB, et al.: A large cohort study of long-term daily use of adult-strength
aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-615.
11. Cook NR, Lee IM, Gaziano JM, et al.: Low-dose aspirin in the primary prevention of cancer. The
Women’s Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
12. Gann PH, Manson JE, Glynn RJ, et al.: Low-dose aspirin and incidence of colorectal tumors in a
randomized trial. J Natl Cancer Inst 1993;85:1220-1224.
13. Peto R, Gray R, Collins R, et al.: Randomized trial of prophylactic daily aspirin in British male doctors.
BMJ 1988;296:313-316.
14. Farrell B, Godwin J, Richards S, et al.: The United Kingdom transient ischaemic attack (UK-TIA)
aspirin trial: final results.
15. Benamouzig R, Deyra J, Martin A, et al.: Daily soluble aspirin and prevention of colorectal adenoma
recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-336.
16. Baron JA, Cole BF, Sandler RS, et al.: A randomized trial of aspirin to prevent colorectal adenomas. N
Engl J Med 2003; 348:891-899.
17. Andrew T. Chan, Edward L., Giovannucci, Jeffrey A., Meyerhardt, Eva S., Schernhammer, Kana Wu,
and Charles S. Fuchs,: Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men
Gastroenterology 2008;134:21-28.
18. Hayden M, Pignone M, Phillips C, et al.: Aspirin for the primary prevention of cardiovascular events:
Gastro 2009.qxd 5/9/2009 1:41 PM Page 258
A vastagbél 259
a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172.
19. Ridker PM, Cook NR, Lee I-M, et al.: A randomized trial of low-dose aspirin in the primary prevention
of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
20. Ridker PM, Cook NR, Lee I-M, et al.: A randomized trial of low-dose aspirin in the primary prevention
of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
21. David J. Kerr, M.D., Janet A. Dunn, Ph.D., Michael J. Langman, M.D., Justine L. Smith, B.Sc., Rachel
S.J. Midgley, M.D., Andrew Stanley, M.Phil., Joanne C. Stokes, B.Sc., Patrick Julier, M.Sc., Claire
Iveson, B.Sc., Ravi Duvvuri, B.Sc., Christopher C. McConkey, M.Sc., for the VICTOR Trial Group:
Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer N Engl J
Med Volume 357:360-369 July 26, 2007 Number 4.
22. Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in
familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
23. Baron JA, Sandler RS, Bresalier RS, et al.: Approve trial investigators. A randomized trial of rofecoxib
for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-1682.
24. Bertagnolli MM, Eagle CJ, Zauber AG, et al.: APC Study Investigators. Celecoxib for the prevention
of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884.
25. Arber N, Eagle C, Spicak J, et al.: A randomized controlled trial of celecoxib for prevention of colorectal
sporadic adenomatous polyps (PreSAP). N Engl J Med 2006;355:885-895.
26. Gradilone, A.; Pulcinelli, F. M.; Lotti, L. V.; Trifiro, E.; Martino, S.; Gandini, O.; Gianni, W.; Frati, L.;
Agliano, A. M.; Gazzaniga, P. Celecoxib: Upregulates Multidrug Resistance Proteins in Colon Cancer:
Lack of Synergy with Standard Chemotherapy Current Cancer Drug Targets, Volume 8, Number 5,
August 2008, pp. 414-420(7).
27. Cross JT, Pool EM, Ulrich CM.: A review of gene-drug interactions for nonsteroidal anti-inflammatory
drug use in preventing colorectal neoplasia. Pharmacogenomics J 2008;15:
28. Rao CV, Reddy BS, Steele VE, et al.: Nitric oxide-releasing aspirin and indomethacin are potent
inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer
Ther 2006;5:1530-1538.
29. Tareisha Dunlapa, Samer O. Abdul-Haya, R. Esala P. Chandrasenaa, Ghenet K. Hagosa, Vaishali Sinhaa,
Zhiqiang Wanga, Huali Wanga and Gregory R.J. Thatcher: Nitrates and NO-NSAIDs in cancer
chemoprevention and therapy: In vitro evidence querying the NO donor functionality Nitric Oxide Volume
19, Issue 2, September 2008, Pages 115-124 Nitric Oxide and Cancer: Clinical and Therapeutic Implications.
30. Ghenet K Hagos 1, Samer O Abdul-Hay 1, Johan Sohn 1, Praneeth D Edirisinghe 1, Zhiqiang Wang 1, R.
Esala P Chandrasena 1, Qian Li 1, Gregory R Thatcher: 1 Anti-inflammatory, antiproliferative, and
cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention Molecular Pharmacology
Fast Forward First published on August 1, 2008; DOI: 10.1124/mol.108.046664.
31. Eaden J, Abrams K, Ekbom A, et al.: Colorectal cancer prevention in ulcerative colitis: a case-control
study. Aliment Pharmacol Ther 2000; 14:145-153.
32. van Staa TP, Card T, Logan RF, Leufkens HG.: 5-Aminosalicylate use and colorectal cancer risk in inflammatory
bowel disease: a large epidemiological study. 1: Gut. 2005 Nov;54(11):1573-8. Epub 2005 Jun 30.
33. Schmiegel W, Pox CP, Reiser M. German 5-ASA Polyp Prevention Study Group (GAPPS).: Effect of
5-aminosalicylate (5-ASA) on the recurrence rate of sporadic colorectal adenomas (abstr). Gastroenterology
2004;126(Suppl 2):A-452.
34. Carmine Stolfi, Roberto Pellegrini, Eleonora Franze, Francesco Pallone, Giovanni Monteleone:
Molecular basis of the potential of mesalazine to prevent colorectal cancer World J Gastroenterol 2008
July 28; 14(28): 4434-4439.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 259
260 Gastro Update 2009
35. Stolfi C, Fina D, Caruso R, Caprioli F, Fantini MC, Rizzo A, Sarra M, Pallone F, Monteleone G.:
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer
cells in S phase. 1: Carcinogenesis. 2008 Jun;29(6):1258-66. Epub 2008 May 20.
36. Zhang H, Ye Y, Bai Z, Wang S.: The COX-2 selective inhibitor-independent COX-2 effect on colon
carcinoma cells is associated with the Delta1/Notch1 pathway. 1: Dig Dis Sci. 2008 Aug;53(8):2195-203.
Epub 2008 Mar 5.
37. Bonovas S, Filioussi K, Tsavaris N, et al.: Statins and cancer risk: a literature-based meta-analysis and
meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-4817.
38. Liudmila L. Kodach, Sylvia A. Bleuming, Maikel P. Peppelenbosch, Daniel W. Hommes, Gijs R. van den
Brink, James C.H. Hardwick: The Effect of Statins in Colorectal Cancer Is Mediated Through the
Bone Morphogenetic Protein Pathway, Gastroenterology Volume 133, Issue 4, Pages 1272-1281
(October 2007).
39. Zimber, Amazia; Gespach, Christian Bile: Acids and Derivatives, Their Nuclear Receptors FXR, PXR
and Ligands: Role in Health and Disease and Their Therapeutic Potential Anti-Cancer Agents in Medicinal
Chemistry (Formerly Current Medicinal Chemistry, Volume 8, Number 5, June 2008, pp. 540-563(24).
40. Edward V. Loftus, Jr. MD: Epidemiology and Risk Factors for Colorectal Dysplasia and Cancer in
Ulcerative Colitis Gastroenterology Clinics of North America Volume 35, Issue 3, September 2006,
Pages 517-531.
41. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD.: Ursodeoxycholic acid as a chemopreventive
agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;
124: 889-893.
42. Timothy L Zisman, David T Rubin: Colorectal cancer and dysplasia in inflammatory bowel disease
ISSN 1007-9327 CN 14-1219/R World J Gastroenterol 2008 May 7; 14(17): 2662-2669.
43. J. M. Wolf, L. A. Rybicki & B. A. Lashner: The impact of ursodeoxycholic acid on cancer, dysplasia and
mortality in ulcerative colitis patients with primary sclerosing cholangitis Volume 22 Issue 9 Page 783-788,
November 2005.
44. Alberts DS, Einspahr JG, Earnest DL, et al.: Fecal bile acid oncentrations in a subpopulation of the
wheat bran fiber colon polyp trial. Cancer Epidemiol Biomarkers Prev 2003;12:197-200.
45. Herszényi, László; Farinati, Fabiob; Miheller, Pála; Tulassay, Zsolt: Chemoprevention of colorectal
cancer: feasibility in everyday practice? European Journal of Cancer Prevention:Volume 17(6)
November 2008pp 502-514.
46. Luk GD, Baylin SB.: Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med
1984;311:80-83.
47. Hixson LJ, Garewal HS, McGee DL, et al.: Ornithine decarboxylase and polyamines in colorectal
neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 1993;2:369-374.
48. 86. Giovannucci E.: Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002;31:925-943.
49. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al.: for the Women’s Health Initiative Investigators.
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991-1004.
50. Newcomb PA, et al.: Cancer Res. 2007 Aug 1;67(15):7534-9.
51. Sanjoaquin MA, Allen N, Couto E, et al.: Folate intake and colorectal cancer risk: a meta-analytical
approach, Int J Cancer 2005;113:825-828.
52. Giovannucci E, Stampfer MJ, Colditz GA, et al.: Multivitamin use, folate, and colon cancer in women
in the Nurses’ Health Study. Ann Intern Med 1998;129:517-524.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 260
A vastagbél 261
53. Terry P, Jain M, Miller AB, et al.: Dietary intake of folic acid and colorectal cancer risk in a cohort of
women. Int J Cancer 2002; 97:864-867.
54. La Vecchia C, Negri E, Pelucchi C, et al.: Dietary folate and colorectal cancer. Int J Cancer
2002;102:545-547.
55. Cole BF, Baron JA, Sandler RS, et al.: Folic acid for the prevention of colorectal adenomas: a randomized
clinical trial. JAMA 2007;297:2351-2359.
56. World Cancer Research Fund (WCRF) Panel (Potter JD, Chair).: Diet, nutrition, and the prevention of
cancer: a global perspective. Washington (DC): WCRF/American Institute of Cancer Research; 1997.
57. Gomez A, Salguero G, Garcia H, Aristizabal F, Gutierrez O, Angel LA, Padron J, Martinez C, Martinez H,
Malaver O, Barvo R, Giraldo A.: [Detection mutations in the DNA mismatch repair genes of hMLH1
and hMSH2 genes in Colombian families with suspicion of hereditary non-polyposis colorectal carcinoma
(Lynch syndrome)] Biomedica 2005; 25 (3): 315-324.
58. Heavey PM, McKenna D, Rowland IR.: Colorectal cancer and the relationship between genes and the
environment. Nutr Cancer 2004; 48: 124-141.
59. van der Meer-van Kraaij C, Kramer E, Jonker-Termont D, Katan MB, van der Meer R, Keijer J.:
Differential gene expression in rat colon by dietary heme and calcium. Carcinogenesis 2005; 26: 73-79.
60. Janne P, Mayer R.: Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-1968.
61. Fuszek P, Lakatos P, Tabak A, Papp J, Nagy Z, Takacs I, Horvath HC, Lakatos PL, Speer G.: Relationship
between serum calcium and CA 19-9 levels in colorectal cancer. World J Gastroenterol. 2004 Jul 1;
10(13):1890-2.PMID: 15222030 [PubMed – indexed for MEDLINE] Related Articles.
62. Baron JA, Beach M, Mandel JS, et al.: Calcium supplements for the prevention of colorectal adenoma.
Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-107.
63. Bonithon-Kopp C, Kronborg O, Giacosa A, et al.: Calcium and fiber supplementation in prevention of
colorectal adenoma recurrence: a randomized intervention trial. European Cancer Prevention Organization
Study Group. Lancet 2000;356:1300-1306.
64. Wu K, Willett WC, Fuchs CS, et al.: Calcium intake and risk of colon cancer in women and men. J Natl
Cancer Inst 2002;94:437-446.
65. Subhas Chakrabarty, Venugopal Radjedirane, Henry Appelman, James Varani.: Extracellular Calcium
Sensin Receptor Function in Human Colon Carcinomas: Promotion of E-Cadherin Expression and
Suppression of ß-Catein/TCF Activation Cancer Research 2003; 63: 67-71.
66. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL,
Thun MJ.: Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States
men. Cancer Epidemiol Biomarkers Prev 2003; 12: 597-603.
67. Gorham ED, Garland CF, Garland FC, et al.: Vitamin D and prevention of colorectal cancer. J Steroid
Biochem Mol Biol 2005;97:179-194.
68. Kesse E, Boutron-Ruault MC, Norat T, et al.: Dietary calcium, phosphorus, vitamin D, dairy products
and the risk of colorectal adenoma among French women of the E3N-EPIC prospective study. Int J
Cancer 2005;117:137-144.
69. Wactawski-Wende J, Kotchen JM, Anderson GL, et al.: Women’s Health Initiative Investigators. Calcium
plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-696.
70. Forman MR, Levin B.: Calcium plus vitamin D3 supplementation and colorectal cancer in women. N
Engl J Med 2006;354:752-754.
71. Lappe JM, Travers-Gustafson D, Davies KM, et al.: Vitamin D and calcium supplementation reduces
Gastro 2009.qxd 5/9/2009 1:41 PM Page 261
262 Gastro Update 2009
cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591.
72. Bostick RM, Potter JD, McKenzie DR, et al.: Reduced risk of colon cancer with high intake of vitamin E:
the Iowa Women’s Health Study. Cancer Res 1993;53:4230-4237.
73. Bostick RM, Potter JD, McKenzie DR, et al.: Reduced risk of colon cancer with high intake of vitamin E:
the Iowa Women’s Health Study. Cancer Res 1993;53:4230-4237.
74. Bjelakovic G, Nikolova, D.: Antioxidant supplements for prevention of gastrointestinal cancers; a
systematic analysis. Lancet 2004;364:1219-1228.
75. Jacobs ET, Jiang R, Alberts DS, et al.: Selenium and colorectal adenoma: results of a pooled analysis.
J Natl Cancer Inst 2004;96:1669-1675.
76. Clark LC, Combs GF, Turnbull BW, et al.: Effects of selenium supplementation for cancer prevention
in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer
Study Group. J Am Med Assoc 1996;276: 1957-1963.
77. Ravn-Haren G, Krath BN, Overvad K, Cold S, Moesgaard S, Larsen EH, Dragsted LO.: Effect of
long-term selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic
metabolising enzymes in healthy elderly volunteers from the Danish Prevention of Cancer by Intervention
by Selenium (PRECISE) pilot study. 1: Br J Nutr. 2008 Jun;99(6):1190-8. Epub 2007 Dec 6.
78. Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial
SWOG-S0000 Verified by National Cancer Institute (NCI), November 2008.
79. Mugdha Sukhthankar, Kiyoshi Yamaguchi, Seong-Ho Lee, Michael F. McEntee, Thomas E. Eling,
Yukihiko Haras, Seung Joon Baek: A Green Tea Component Suppresses Posttranslational Expression
of Basic Fibroblast Growth Factor in Colorectal Cancer Gastroeneterology Volume 134, Issue 7, Pages
1972-1980 (June 2008).
80. Dr. Fuszek Péter: A vastagbélrák kemoprevenciója Medical Tribune VI. évfolyam, 5. szám (2008.
március. 13.)
81. Agarwal B, Rao CV, Bhendwal S, et al.: Lovastatin augments sulindac-induced apoptosis in colon cancer
cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999;117:838-847.
82. Reddy BS, Wang CX, Kong AN, et al.: Prevention of azoxymethane-induced colon cancer by combination
of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006;66:4542-4546.
83. Lev-Ari S, Strier L, Kazanov D, et al.: Celecoxib and curcumin synergistically inhibit the growth of
colorectal cancer cells. Clin Cancer Res 2005;11:6738-6744.
84. Nadir Arber and Bernard Levin: Reviews in basic and clinical gastroenterology, Gastroenterology
2008;134:1224-1237.
